Methods and compositions for enriching DHA levels in the brain
Described herein are at least compounds and formulations that can be or contain a docosahexaenoic acid-lysophosphatidylcholine (DHA-LPC) and/or eicosapenteanoic acid-lysophosphatidylcholine (EPA-LPC). Also described herein are at least methods of making and using the compositions and formulations DHA-LPC and/or EPA-LPC.
1. A compound according to Formula 1
wherein R 1 is —OH, and wherein R 2 is EPA, or
wherein R 1 is eicosapentaenoic acid (EPA), and wherein R 2 is —OH.
2. The compound according to claim 1 , wherein R 2 is OH.
3. The compound according to claim 1 , wherein R 1 is OH and R 2 is EPA.
4. A formulation comprising:
a compound according to Formula 1
wherein R 1 is —OH, and wherein R 2 is EPA, or
wherein R 1 is eicosapentaenoic acid (EPA), and wherein R 2 is —OH; and
a pharmaceutically acceptable carrier.
5. The formulation of claim 4 , wherein the compound according to Formula 1 is encapsulated by a micelle, forms a micelle, or is incorporated into the membrane of a vesicle.
6. The formulation of claim 5 , wherein the micelle or vesicle further comprises a cholesterol, phosphatidylcholine, a fatty acid, a monoolein, or any combination thereof.
7. The formulation of claim 4 , wherein the amount of the compound according to Formula 1 is an effective amount.
8. The formulation of claim 7 , wherein the amount of the compound according to Formula 1 is an amount effective to treat depression.
9. The formulation of claim 7 , wherein the amount of the compound according to Formula 1 is an amount effective to treat a neurological disease or disorder.
10. The formulation of claim 9 , wherein the neurological disease or disorder is Alzheimer's disease, Parkinson's, or a traumatic brain injury.
11. The formulation of claim 7 , wherein the amount of the compound according to Formula 1 is an amount effective to enhance the cognitive function in a subject.
12. The formulation of claim 7 , wherein the amount of the compound according to Formula 1 is an amount effective to increase the levels of DHA, EPA, or DHA and EPA in the brain of a subject.
13. The formulation of claim 4 , wherein the formulation is a dietary supplement.
14. The formulation of claim 4 , wherein the formulation is a functional food item.
15. A method comprising:
administering an amount of a compound according to Formula 1
to a subject, wherein R 1 is —OH, and wherein R 2 is EPA, or
wherein R 1 is eicosapentaenoic acid (EPA), and wherein R 2 is —OH.
16. The method of claim 15 , wherein the subject has or is suspected of having a neurological disease or disorder.
17. The method of claim 16 , wherein the neurological disease or disorder is depression, Alzheimer's, Parkinson's, or a traumatic brain injury.
18. The method of claim 15 , wherein the amount of the compound according to Formula 1 is an amount effective to increase the amount of DHA, EPA, or DHA and EPA in the brain of the subject.
19. The method of claim 15 , wherein the amount of the compound according to Formula 1 is an amount effective to treat a neurological disease or disorder.
20. The method of claim 19 , wherein the neurological disease or disorder is depression, Alzheimer's, Parkinson's, or a traumatic brain injury.